Cas no 80681-45-4 (prim-O-Glucosylcimifugin)
prim-O-Glucosylcimifugin Chemical and Physical Properties
Names and Identifiers
-
- prim-O-Glucosylcimifugin
- CIMIFUGIN BETA-D-GLUCOPYRANOSIDE
- glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-,(2S)-
- (2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one
- 5H-Furo[3,2-g][1]benzopyran-5-one,7-[(b-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-,(2S)-
- HMS2196A10
- N1606
- (2S)-7-[(beta-D-Glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-5H-furo[3,2-g][1]benzopyran-5-one
- Q-100837
- (2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrouro[3,2-g]chromen-5-one
- (S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-2,3-dihydro-5H-furo[3,2-g]chromen-5-one
- MFCD09037394
- s9029
- CHEMBL1734606
- CIMIFUGINBETA-D-GLUCOPYRANOSIDE
- ZB1876
- 5H-Furo[3,2-g][1]benzopyran-5-one, 7-[(beta-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (S)-
- AKOS037514796
- CS-3795
- 80681-45-4
- 5H-Furo[3,2-g][1]benzopyran-5-one,7-[(b-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (S)-
- CCG-269432
- HY-N0635
- MLS002472946
- Cimicifuga glycoside
- CHEBI:187279
- DTXSID90554764
- G0535
- (S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-2H-furo[3,2-g]chromen-5(3H)-one
- Cimifugin 7-glucoside
- prim-O-glucosyl cimifugin
- NZ97LQV2BL
- [(2S)-2-(2-Hydroxypropan-2-yl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g][1]benzopyran-7-yl]methyl beta-D-glucopyranoside
- SMR001397054
- AS-76831
- prim-O-b-D-Glucosylcimifugin
- AC-34700
- (2S)-7-[(β-D-Glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-5H-furo[3,2-g][1]benzopyran-5-one (ACI)
- 5H-Furo[3,2-g][1]benzopyran-5-one, 7-[(β-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (S)- (ZCI)
- (2S)-2-(2-HYDROXYPROPAN-2-YL)-4-METHOXY-7-({[(2R,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}METHYL)-2H,3H-FURO[3,2-G]CHROMEN-5-ONE
-
- MDL： MFCD09037394
- Inchi： 1S/C22H28O11/c1-22(2,28)15-5-10-12(32-15)6-13-16(20(10)29-3)11(24)4-9(31-13)8-30-21-19(27)18(26)17(25)14(7-23)33-21/h4,6,14-15,17-19,21,23,25-28H,5,7-8H2,1-3H3/t14-,15+,17-,18+,19-,21-/m1/s1
- InChI Key： XIUVHOSBSDYXRG-UVTAEQIVSA-N
- SMILES： O(C1C2C[C@H](OC=2C=C2OC(=CC(C=12)=O)CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C(O)(C)C)C
Computed Properties
- Exact Mass: 468.16300
- Monoisotopic Mass: 468.16316171 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 5
- Hydrogen Bond Acceptor Count: 11
- Heavy Atom Count: 33
- Rotatable Bond Count: 6
- Complexity: 755
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 6
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Molecular Weight: 468.4
- XLogP3: -0.9
- Topological Polar Surface Area: 164?2
Experimental Properties
- Color/Form: Powder
- Density: 1.5380
- Melting Point: 120°C(lit.)
- Boiling Point: 736.9°C
- Flash Point: 736.861 °C at 760 mmHg
- Refractive Index: 1.648
- PSA: 168.28000
- LogP: -0.80750
- λmax: 296(EtOH)(lit.)
prim-O-Glucosylcimifugin Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Safety Instruction： 24/25
- Storage Condition：4°C, protect from light
prim-O-Glucosylcimifugin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-N0635-10mM*1mLinDMSO |
Prim-O-glucosylcimifugin |
80681-45-4 | 99.94% | 10mM*1mLinDMSO |
￥515 | 2023-07-26 | |
| MedChemExpress | HY-N0635-5mg |
Prim-O-glucosylcimifugin |
80681-45-4 | 99.94% | 5mg |
￥500 | 2025-04-16 | |
| MedChemExpress | HY-N0635-10mg |
Prim-O-glucosylcimifugin |
80681-45-4 | 99.94% | 10mg |
￥850 | 2025-04-16 | |
| S e l l e c k ZHONG GUO | S9029-1mg |
Prim-o-glucosylcimifugin |
80681-45-4 | 99.88% | 1mg |
￥794.72 | 2023-09-15 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P117974-20mg |
prim-O-Glucosylcimifugin |
80681-45-4 | ,>98% | 20mg |
￥489.90 | 2023-09-01 | |
| ChemFaces | CFN98104-20mg |
Prim-O-glucosylcimifugin |
80681-45-4 | >=98% | 20mg |
$70 | 2021-07-22 | |
| HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI | BZP0278-20mg |
prim-O-Glucosylcimifugin |
80681-45-4 | HPLC≥98% | 20mg |
￥500元 | 2023-09-15 | |
| DC Chemicals | DCS-004-20 mg |
Prim-O-glucosylcimifugin |
80681-45-4 | >98%, Standard References Grade | 20mg |
$280.0 | 2022-02-28 | |
| TRC | P213430-5mg |
Prim-O-glucosylcimifugin |
80681-45-4 | 5mg |
$ 190.00 | 2022-06-03 | ||
| TRC | P213430-10mg |
Prim-O-glucosylcimifugin |
80681-45-4 | 10mg |
$ 310.00 | 2022-06-03 |
prim-O-Glucosylcimifugin Suppliers
Audited Supplier
Audited Supplier
prim-O-Glucosylcimifugin Related Literature
-
Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
-
Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
-
Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
-
Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
Additional information on prim-O-Glucosylcimifugin
Prim-O-Glucosylcimifugin: A Comprehensive Overview
Prim-O-glucosylcimifugin, a compound with the CAS number 80681-45-4, is a bioactive natural product that has garnered significant attention in recent years due to its diverse pharmacological activities and potential applications in the fields of medicine and nutraceuticals. This compound, primarily found in certain medicinal plants, exhibits a unique chemical structure that contributes to its versatile biological functions.
The chemical structure of prim-O-glucosylcimifugin is characterized by a flavonoid backbone with a specific glycosylation pattern. This glycosylation plays a crucial role in enhancing the compound's stability, bioavailability, and bioactivity. Recent studies have highlighted the importance of understanding the stereochemistry and regiochemistry of this compound, as these factors significantly influence its pharmacokinetic properties and therapeutic effects.
One of the most notable aspects of prim-O-glucosylcimifugin is its antioxidant activity, which has been extensively studied in vitro and in vivo. Research has demonstrated that this compound effectively scavenges free radicals and inhibits oxidative stress, making it a promising candidate for the development of anti-aging and neuroprotective agents. Furthermore, prim-O-glucosylcimifugin has shown potent anti-inflammatory properties, which could be beneficial in treating chronic inflammatory diseases such as arthritis and cardiovascular disorders.
The anti-cancer potential of prim-O-glucosylcimifugin is another area of active research. Studies have revealed that this compound can induce apoptosis in various cancer cell lines while exhibiting minimal toxicity to normal cells. Additionally, it has been found to synergize with conventional chemotherapy drugs, enhancing their efficacy while reducing their side effects. These findings underscore the potential of prim-O-glucosylcimifugin as a complementary therapy in oncology.
In terms of synthesis, prim-O-glucosylcimifugin can be isolated from its natural sources or synthesized through semi-synthetic routes. Recent advancements in enzymatic glycosylation have enabled the precise control over the glycosylation pattern, leading to higher yields and improved quality of the final product. These developments are expected to facilitate large-scale production of prim-O-glucosylcimifugin for commercial applications.
Recent research has also explored the pharmacokinetics and bioavailability of prim-O-glucosylcimifugin. Studies conducted in animal models have shown that this compound exhibits moderate absorption and rapid elimination, suggesting the need for formulation strategies to enhance its bioavailability. Encapsulation techniques such as nanoemulsions and liposomal delivery systems have been proposed as effective methods to improve the oral delivery of prim-O-glucosylcimifugin.
The application of prim-O-glucosylcimifugin extends beyond pharmacology into the field of cosmetology. Its anti-aging and skin protective properties have made it a valuable ingredient in premium skincare products. Clinical trials have demonstrated that topical application of prim-O-glucosylcimifugin can reduce oxidative damage to skin cells and improve overall skin health.
In conclusion, prim-O-glucosylcimifugin (CAS No. 80681-45-4) is a multifaceted natural compound with immense therapeutic potential. Its unique chemical structure, coupled with its diverse biological activities, positions it as a key player in drug discovery and development. As research continues to uncover new insights into its mechanisms of action and applications, prim-O-glucosylcimifugin is poised to make significant contributions to various industries ranging from pharmaceuticals to cosmetics.
